share_log

双鹭药业(002038.SZ):公司没有司美格鲁肽研发

Shuanglu Pharmaceutical (002038.SZ): The company has no Smegalotide R&D

Gelonghui Finance ·  Nov 20, 2023 06:30

Gelonghui November 20 | Shuanglu Pharmaceutical (002038.SZ) said on the investor interactive platform that the company has not developed simeglutide, but the company's GLP-1 long-acting drug, duracylotide, has now completed phase III clinical enrollment and is expected to complete clinical research in the first half of next year; the GLP-1 preparation, liraglutide, is in the clinical data compilation stage. It is expected that all phase III participants will be followed up. It is expected that registration applications will be submitted next year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment